Oct 17, 2016 7:30 am EDT Heat Biologics to Present at Two Upcoming Investor Conferences and Panel Discussion
Oct 13, 2016 7:00 am EDT Heat Biologics Remains on Track to Achieve Multiple Topline Data Readouts this Quarter
Oct 11, 2016 7:30 am EDT Heat Biologics Selects Adaptive Biotechnologies to Discover Potential Clinical Biomarkers to Advance Novel Immunotherapies
Oct 07, 2016 7:00 am EDT Heat Biologics Substantially Reduces Debt and Reports Proceeds of Approximately $2.8 Million Year-to-Date from the Exercise of Warrants
Sep 14, 2016 7:00 am EDT Heat Biologics Resumes Enrollment in its Non-Small Cell Lung Cancer Trial Evaluating HS-110 in Combination with Anti-PD-1 Checkpoint Inhibitor
Aug 15, 2016 4:15 pm EDT Heat Biologics Provides Corporate Update and Reports Second Quarter 2016 Financial Results
Jul 22, 2016 8:00 am EDT Heat Biologics Announces Suspension of Proposed Public Offering of Common Stock